You are currently browsing the tag archive for the ‘TCM’ tag.
Arthur Goldgaber
Market Analyst
SmallcapInsights.com
To view the PDF of this white paper, written by Market Analyst Arthur Goldgaber, please click here.
Dr. John L. Faessel
ON THE MARKET
Commentary and Insights
Faessel Publishing LLC
Dr.Faessel@onthemar.com
Strikingly Undervalued Metrics while Maintaining Exceptional Profit & Revenue Growth
Bohai Pharmaceuticals Group Inc. (OTCBB/OTCQB: BOPH) $2.20
Unless you’ve just recovered consciousness out of a 10-year coma or just back from a trip exploring the cosmos you know that China is “the” economic phenomena of this new century. Chinese companies are benefiting from both macro and micro trends that are the making of historic, tremendously bullish scenarios. This profitable, undervalued, and undiscovered Chinese pharmaceutical company fits that description to a T…
(BOPH) manufactures and distributes traditional Chinese herbal medicines and other products that are used for common health problems such as rheumatism, rheumatoid arthritis, respiratory diseases, viral infections, gynecological diseases and cardiovascular issues. Key is that the company’s 15 traditional pharmaceutical products carry the U.S. equivalent of government licenses and certain key products are “protected” and one has a patent lasting 20 years. Read the rest of this entry »
SmallcapInsights.com 
Health Care Reform in China Boosts Sales of Traditional Chinese Medicine
January 13, 2011 in Market Commentary | Tags: China, EDL, Government Reimbursement, Growth Potential, Healthcare, Medical Services, NDRL, Pharmaceuticals, PRC Policies, Reform, TCM, Traditional Chinese Medicine | by The Editors | Leave a comment
Arthur Goldgaber
Market Analyst
SmallcapInsights.com
To view the PDF of this white paper, written by Market Analyst Arthur Goldgaber, please click here.